Equities Analysts Offer Predictions for IRWD Q3 Earnings

Key Points

• Zacks Research analysts have revised their earnings estimates for Ironwood Pharmaceuticals (IRWD), now projecting a Q3 2025 EPS of $0.07, down from $0.08.
• Wall Street Zen upgraded IRWD shares from a "hold" to a "strong-buy" rating, with the stock currently having an average target price of $4.94.
• Ironwood Pharmaceuticals showed positive performance in its last earnings report, with a reported EPS of $0.14, exceeding expectations by $0.16 and generating revenue of $85.24 million.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Investment analysts at Zacks Research decreased their Q3 2025 earnings per share (EPS) estimates for shares of Ironwood Pharmaceuticals in a report issued on Thursday, August 28th. Zacks Research analyst Team now expects that the biotechnology company will post earnings per share of $0.07 for the quarter, down from their previous forecast of $0.08. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals' Q1 2026 earnings at $0.01 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.13 EPS, Q4 2026 earnings at $0.15 EPS, FY2026 earnings at $0.37 EPS and Q2 2027 earnings at $0.00 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.16. The firm had revenue of $85.24 million for the quarter, compared to analysts' expectations of $62.02 million. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS.

Separately, Wall Street Zen upgraded Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. One analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $4.94.

Ironwood Pharmaceuticals Trading Down 10.9%

IRWD stock traded down $0.14 during trading hours on Monday, hitting $1.11. 2,487,021 shares of the stock were exchanged, compared to its average volume of 2,764,364. The firm has a market capitalization of $179.49 million, a P/E ratio of -22.10 and a beta of 0.33. The company has a 50-day simple moving average of $0.92 and a two-hundred day simple moving average of $1.01. Ironwood Pharmaceuticals has a 12 month low of $0.53 and a 12 month high of $5.13.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IRWD. Armistice Capital LLC lifted its stake in shares of Ironwood Pharmaceuticals by 44.7% in the 1st quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company's stock valued at $20,139,000 after acquiring an additional 4,232,000 shares during the last quarter. Millennium Management LLC grew its stake in shares of Ironwood Pharmaceuticals by 186.6% in the first quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company's stock worth $9,349,000 after purchasing an additional 4,140,439 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Ironwood Pharmaceuticals by 147.6% in the second quarter. Acadian Asset Management LLC now owns 6,549,687 shares of the biotechnology company's stock worth $4,685,000 after purchasing an additional 3,904,498 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Ironwood Pharmaceuticals by 144.3% in the second quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company's stock worth $4,422,000 after purchasing an additional 3,641,762 shares during the last quarter. Finally, Marshall Wace LLP grew its stake in shares of Ironwood Pharmaceuticals by 616.3% in the second quarter. Marshall Wace LLP now owns 3,993,557 shares of the biotechnology company's stock worth $2,875,000 after purchasing an additional 3,436,036 shares during the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.